Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

GSK and Shenzhen Neptunus Create Flu Vaccine JV

publication date: Jun 9, 2009

GlaxoSmithKline has formed a vaccine JV with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT), an established China vaccine company. The JV will produce flu vaccines for the China market. It will seek to increase GSK’s presence in emerging markets, which is one of the company’s long-term strategic goals. Also, the JV benefits GSK by using its vaccine adjuvant. More details...

Stock Symbol: (NYSE: GSK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital